AngioDynamics (NASDAQ:ANGO) Posts Earnings Results

AngioDynamics (NASDAQ:ANGO) announced its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07, FiscalAI reports. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.43%. The firm had revenue of $80.92 million during the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

Here are the key takeaways from AngioDynamics’ conference call:

• Revenue grew 6.9% to $80.9 million, driven by 13.2% growth in Med Tech, which now represents 49% of sales and is expected to become the majority of revenue this fiscal year. Med Device revenue grew a steadier 1.4% and continues to provide cash flow for Med Tech investments.
• Key growth platforms continued to perform well: Auryon delivered its 21st consecutive quarter of double-digit growth, AlphaVac revenue rose 37.4%, and NanoKnife revenue increased 29% on record prostate procedure volumes. Management cited further catalysts from AlphaReturn trial enrollment, broader NanoKnife reimbursement, and the RELIEF BPH study.
• Profitability improved, with adjusted EBITDA rising to $5.0 million from $2.2 million and adjusted loss per share narrowing to $0.04 from $0.10. Gross margin reached 59.4%, or 57.8% excluding tariff refunds, supported by pricing and favorable product mix.
• Management maintained fiscal 2027 guidance for revenue of $336 million–$341 million, Med Tech growth of 12%–15%, gross margin of 54%–55%, adjusted EBITDA of $13 million–$16 million, and an adjusted loss per share of $0.29–$0.24. The company expects positive operating cash flow for the full year, although it ended the quarter with $34 million in cash after using $15.3 million in operating cash.
• CEO Jim Clemmer will retire, with Eric Honroth appointed as president and CEO effective November 2; management characterized the transition as planned and expressed confidence in Honroth’s medical-device leadership experience. AngioVac revenue declined 5.9% year over year due to a difficult comparison, though sequential growth and underlying demand were described as improving.

AngioDynamics Stock Performance

Shares of ANGO opened at $11.52 on Friday. AngioDynamics has a fifty-two week low of $9.39 and a fifty-two week high of $16.29. The company has a 50 day moving average price of $15.32 and a 200-day moving average price of $13.10. The stock has a market capitalization of $484.46 million, a PE ratio of -14.77 and a beta of 0.30.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on ANGO shares. HC Wainwright lifted their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of AngioDynamics in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Adjusted earnings beat expectations. AngioDynamics reported fiscal Q1 2027 adjusted EPS of a $0.04 loss, better than the $0.11 loss analysts expected. Revenue reached $80.9 million, slightly above consensus and up 6.9% year over year. Zacks earnings report
• Positive Sentiment: Med Tech growth and margins were strong. Med Tech sales rose 13.2% to $39.9 million, led by 14.7% growth in Auryon sales and 29% growth in NanoKnife sales. Gross margin expanded 410 basis points to 59.4%, while the GAAP net loss narrowed from the prior year. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics fiscal Q1 results
• Positive Sentiment: Canaccord reaffirmed its Buy rating and set a $20 price target, implying substantial potential upside from the referenced share price. Benzinga report
• Neutral Sentiment: Fiscal 2027 guidance was reiterated: revenue of $336 million to $341 million and an adjusted EPS loss of $0.24 to $0.29. The outlook remains broadly in line with analyst expectations, but it does not yet indicate a return to profitability. Seeking Alpha guidance report
• Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer. The transition adds execution risk even as operating momentum improves. CEO appointment announcement
• Negative Sentiment: Profitability and cash flow remain concerns. AngioDynamics posted a GAAP net loss of $7.1 million and used $15.3 million of operating cash during the quarter. These issues likely overshadowed the adjusted EPS and revenue beats. Reported short-interest data showing zero shares appears inconsistent and should be treated cautiously.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.